Pantoprazole 20/40 mg tabs — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for GERD / Acid Reflux

• Esomeprazole
• Famotidine
• Omeprazole

What Pantoprazole 20/40 mg tabs is approved for (FDA label)

PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets are indicated for: PROTONIX is a proton pump inhibitor (PPI) indicated for the following: • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) • Maintenance of Healing of Erosive Esophagitis ( 1.2 ) • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE).

Source: Read the full FDA label on DailyMed. Label effective date: May 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Pantoprazole 20/40 mg tabs (FDA label)

Delayed-Release Tablets: • 40 mg pantoprazole, yellow oval biconvex tablets imprinted with PROTONIX (brown ink) on one side • 20 mg pantoprazole, yellow oval biconvex tablets imprinted with P20 (brown ink) on one side For Delayed-Release Oral Suspension: • 40 mg pantoprazole, pale yellowish to dark brownish, enteric-coated granules in a unit dose packet • Delayed-Release Tablets: 20 mg and 40 mg pantoprazole ( 3 ) • For Delayed-Release Oral Suspension: 40 mg pantoprazole ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 08098cb2-c048-4640-f387-6beec4a38936. SPL document ID: b1adaee5-9353-48ce-bde4-f169a3787e30. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Pantoprazole 20/40 mg tabs (FDA label)

The following serious adverse reactions are described below and elsewhere in labeling: • Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] • Clostridium difficile- Associated Diarrhea [see Warnings and Precautions (5.3) ] • Bone Fracture [see Warnings and Precautions (5.4) ] • Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5) ] • Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6) ] • Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions (5.7) ] • Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.8) ] • Fundic Gland Polyps [see Warnings and Precautions (5.10) ] Most common adverse reactions are: • For adult use (>2%): headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and arthralgia. ( 6.1 ) • For pediatric use (>4%): URI, headache, fever, diarrhea, vomiting, rash, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience The adverse reaction profiles for PROTONIX (pantoprazole sodium) For Delayed-Release Oral Suspension and PROTONIX (pantoprazole sodium) Delayed-Release Tablets are similar.

Source: FDA prescribing information (DailyMed). Set ID: 08098cb2-c048-4640-f387-6beec4a38936. SPL document ID: b1adaee5-9353-48ce-bde4-f169a3787e30. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Pantoprazole 20/40 mg tabs (FDA label)

• PROTONIX is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2) , Adverse Reactions (6) ] . • Proton pump inhibitors (PPIs), including PROTONIX, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7) ] . • Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles ( 4 ) • Patients receiving rilpivirine-containing products ( 4 , 7 )

Source: FDA prescribing information (DailyMed). Set ID: 08098cb2-c048-4640-f387-6beec4a38936. SPL document ID: b1adaee5-9353-48ce-bde4-f169a3787e30. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Pantoprazole 20/40 mg tabs (FDA label)

• Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy.

Source: FDA prescribing information (DailyMed). Set ID: 08098cb2-c048-4640-f387-6beec4a38936. SPL document ID: b1adaee5-9353-48ce-bde4-f169a3787e30. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Pantoprazole 20/40 mg tabs (FDA label)

Table 4 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with PROTONIX and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 4: Clinically Relevant Interactions Affecting Drugs Co-Administered with PROTONIX and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine atazanavir, and nelfinavir) when used concomitantly with pantoprazole may reduce antiviral effect and promote the development of drug resistance. • Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with pantoprazole may increase toxicity of the antiretroviral drugs . • There are other antiretroviral drugs which do not result in clinically relevant interactions with pantoprazole.

Source: FDA prescribing information (DailyMed). Set ID: 08098cb2-c048-4640-f387-6beec4a38936. SPL document ID: b1adaee5-9353-48ce-bde4-f169a3787e30. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.